跨损伤合成DNA聚合酶ζ-Rev7在肿瘤发展中的研究进展

基础医学与临床 ›› 2018, Vol. 38 ›› Issue (5): 727-730.

跨损伤合成DNA聚合酶ζ-Rev7在肿瘤发展中的研究进展

曹菊华¹,汪良芝²

1. 中国人民解放军第102医院
2. 常州市第一人民医院

收稿日期:2017-05-09 修回日期:2017-09-26 出版日期:2018-05-05 发布日期:2018-04-28
通讯作者: 汪良芝 E-mail:wangdoc371@163.com

Research progress on translesion synthesis DNA polymerase ζ-Rev7 in tumor development

Received:2017-05-09 Revised:2017-09-26 Online:2018-05-05 Published:2018-04-28

摘要/Abstract

摘要： 跨损伤DNA合成（TLS）属于一种复制后修复过程，主要涉及DNA聚合酶κ、η和ζ等。跨损伤修复是细胞内一种DNA损伤耐受机制，DNA聚合酶ζ在这一过程中扮演着重要的角色， DNA聚合酶ζ主要由亚基Rev7和 Rev3构成，在细胞代谢中的作用主要是参与跨损伤修复。Rev7(也称为MAD2L2)是一种多功能蛋白，能够与多种蛋白结合，参与DNA损伤修复、细胞的周期调节、基因表达和致癌作用。同时也参与调控多种不良肿瘤的预后过程。

关键词: DNA聚合酶ζ ，Rev7，肿瘤

Abstract: Translesion DNA synthesis is a kind of post-replication repair process, which mainly involves DNA polymerase kappa, eta and zeta. Translesion synthesis is a tolerance mechanism of DNA damage inside the cell, in which DNA polymerase zeta plays an important role. DNA polymerase zeta is mainly composed of subunits Rev7 and Rev3, and play the main role of participate in the damage repair in cell metabolism. Rev7 (also known as MAD2L2) is a multifunctional protein that can be combined with a variety of proteins to participate in DNA damage repair, cell cycle regulation, gene expression and carcinogenesis, which is also involved in the process of controlling the prognosis of various adverse tumors.

曹菊华汪良芝. 跨损伤合成DNA聚合酶ζ-Rev7在肿瘤发展中的研究进展[J]. 基础医学与临床, 2018, 38(5): 727-730.